The new Senoclaire breast
tomosynthesis system from GE has been granted the CE mark. Powered by ASiR, the
company’s iterative reconstruction algorithm that yields FFDM-like images and
positively impacts micro calcification conspicuity, the Senoclaire’s
three-dimensional imaging technology uses a low-dose short X-ray sweep around
the positioned breast with nine exposures acquired using a “step-and-shoot”
method, thus removing the potential motion from images. A single MLO view
provides clinical non-inferiority compared to a 2-view digital mammography
exam—at half the dose and with just one compression. Subsequently, this
solution has the potential to replace digital mammography exams in screening to
help radiologists detect breast cancer.
In addition, SenoClaire will
help deliver superior sensitivity for architectural distortions and masses,
help improve specificity of lesion margin visibility, and ultimately, help
radiologists reduce recall rates through better characterization of findings.
Finally, its images are compatible with major PACS systems, so that
radiologists can integrate them easily into their environment and get the most
from their investment. Hooman Hakami, President & CEO, GE Healthcare –
Detection & Guidance Solutions said
“GE Healthcare has the broadest array of solutions in the breast care space.
From hardware and software to wetware, we continue to bring new innovations to
the breast care space and integrate them in distinctive ways. With the
introduction of SenoClaire, we are bringing a new generation of breast
tomosynthesis, together with innovative solutions like contrast enhanced spectral
mammography, automated whole breast ultrasound and molecular breast imaging”.
GE Healthcare
Chalfont St. Giles,UK